Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.31 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672167 | 0.82 | ACHE (0.49) | NAMPTKDM5BPRMT5WDR77CTSD | |
| SCHEMBL12419623 | 0.82 | NAMPT (0.51) | NAMPTKDM5BPRMT5WDR77L3MBTL1 | |
| SCHEMBL671710 | 0.80 | L3MBTL1 (0.51) | NAMPTKDM5BPRMT5WDR77L3MBTL1 | |
| SCHEMBL2559356 | 0.80 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL2551385 | 0.78 | KIT (0.37) | NAMPTKDM5BPRMT5WDR77L3MBTL1 | |
| SCHEMBL4212327 | 0.77 | NAMPT (0.34) | NAMPTKDM5BPRMT5WDR77 | |
| SCHEMBL23227826 | 0.77 | L3MBTL1 (0.41) | CTSDBACE1BACE2L3MBTL1ALDH1A1 | |
| SCHEMBL25389216 | 0.77 | ACHE (0.37) | ACHE | |
| SCHEMBL16100862 | 0.77 | NAMPT (0.44) | NAMPTKDM5BPRMT5WDR77CTSD | |
| SCHEMBL23227824 | 0.77 | MAPT (0.33) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-15 | — | — | US | disclosed |
| CN-110191882-B | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 株式会社大熊制药 | 2022-09-13 | — | — | CN | disclosed |
| US-20220227751-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GALAPAGOS NV (BE) | 2022-07-21 | — | — | US | disclosed |
| EP-4019519-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2022-06-29 | — | — | EP | disclosed |
| EP-3378862-B1 | DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF MULTIPLE SCLEROSIS | GALAPAGOS NV (BE) | 2022-03-16 | — | — | EP | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-11220499-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2022-01-11 | — | — | US | disclosed |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-20 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2091951-A2 | PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2009-08-26 | — | — | EP | disclosed |
| CN-101417999-A | Piperazines derivates, preparation method thereof and application thereof in medicine | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2009-04-29 | — | — | CN | disclosed |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2008-10-16 | — | — | US | disclosed |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2008-10-16 | — | — | US | disclosed |
| WO-2008109700-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109697-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PPARA, PPARG, PPARD | NAMPT 1944/4885KDM5B 4740/4885PRMT5 4017/4885 |
| US-20220227751-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GPR84, GPR88, GPR65 | NAMPT 3213/4885KDM5B 4228/4885PRMT5 1997/4885 |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM1B, KDM5D | NAMPT 2739/4885KDM5B 4/4885PRMT5 42/4885 |
| US-11220499-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GPR84, GPR88, GPR65 | NAMPT 3023/4885KDM5B 4179/4885PRMT5 1901/4885 |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | ALK, MET, RET | NAMPT 4110/4885KDM5B 670/4885PRMT5 125/4885 |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | RNASE1, AARS1, DHPS | NAMPT 553/4885KDM5B 2775/4885PRMT5 959/4885 |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARA, PPARD | NAMPT 330/4885KDM5B 4262/4885PRMT5 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.